Ignite Creation Date:
2024-05-05 @ 12:06 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00245063
Status:
COMPLETED
Last Update Posted:
2014-10-02
First Post:
2005-10-25
Brief Title:
AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
Phase II Study of AZD2171 in Patients With Recurrent Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2013-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase II trial is studying how well AZD2171 works in treating patients with recurrent small cell lung cancer AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor
Detailed Description:
PRIMARY OBJECTIVES
I To determine the objective response rate of AZD 2171 in patients with recurrent small cell lung cancer SCLC
SECONDARY OBJECTIVES
I To determine the overall survival and time to progression II To assess the toxicities associated with the administration of AZD 2171 for patients with recurrent SCLC
III To perform molecular correlative studies on archival tumor and peripheral blood
OUTLINE This is a multicenter study
Patients receive oral AZD2171 once daily for 28 days Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
After completion of study treatment patients are followed at 4 weeks
I To determine the objective response rate of AZD 2171 in patients with recurrent small cell lung cancer SCLC
SECONDARY OBJECTIVES
I To determine the overall survival and time to progression II To assess the toxicities associated with the administration of AZD 2171 for patients with recurrent SCLC
III To perform molecular correlative studies on archival tumor and peripheral blood
OUTLINE This is a multicenter study
Patients receive oral AZD2171 once daily for 28 days Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
After completion of study treatment patients are followed at 4 weeks
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| N01CM62209 | NIH | None | httpsreporternihgovquickSearchN01CM62209 |
| PHII-64 | None | None | None |
| N01CM62201 | NIH | None | None |